Natalia Lukashchuk
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, BRCA gene mutations in cancer, Ovarian cancer diagnosis and treatment, Cancer-related Molecular Pathways
Most-Cited Works
- → Mutant p53 Drives Invasion by Promoting Integrin Recycling(2009)799 cited
- → Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response(2012)342 cited
- → Ubiquitination and Degradation of Mutant p53(2007)223 cited
- → Neddylation Promotes Ubiquitylation and Release of Ku from DNA-Damage Sites(2015)128 cited
- → Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy(2021)112 cited
- → Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial(2023)83 cited
- → Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance(2020)62 cited
- → Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer(2024)61 cited
- → Cancer cells suppress p53 in adjacent fibroblasts(2008)60 cited
- → Impact of DNA damage repair alterations on prostate cancer progression and metastasis(2023)36 cited